Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. J of Skin 2018, 2, S78. https://doi.org/10.25251/skin.2.supp.78.